Loading data for GHRS — first visit, this takes a few seconds.

アラート

GH Research (GHRS)

NasdaqGM: GHRS · リアルタイム株価 · USD

27.94

-0.71 (-2.48%)

終値時点： Aug 28, 2026, 8:00 PM

28.16

+0.79%

時間外: 7:52 PM

株価、主要な数字、最新ニュースをひとまとめにしたページです。

-2.48% (1D)

データがありません

買気配	20.99
時価総額	1.92B
売上高（TTM）	n/a
純利益（TTM）	-62.27M
	1.29
	-0.96
	n/a
	-15.1
PBR（TTM）	5.34
PSR（TTM）	n/a
決算発表日	Nov 5, 2026

売気配	36.6
出来高	117,626
平均出来高（20日）	290,316
始値	28.61
前日終値	28.65
当日レンジ	27.85 - 28.61
52週レンジ	11.83 - 31.44
アナリスト	n/a
目標株価	n/a
配当	n/a
権利落ち日	n/a

GHRSについて

GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression. It also develo...

[続きを読む]

業種 Biotechnology

セクター Healthcare

IPO日 Jun 25, 2021

従業員数 73

上場取引所 NasdaqGM

ティッカー GHRS

ウェブサイト https://www.ghres.com

企業情報の全文

業績

2025年のGH Researchの売上高は0で、前年の0からundefined%の増加でした。利益は-48.26Mで、23.86%の増加でした。

財務諸表

決算サプライズ

GH ResearchはAug 6, 2026に四半期決算を発表しました：

売上高は $0 で、予想を下回りました $0, うち NaN% の前年比増加にあたります.
EPSは -0.23 で、予想を上回りました 0.07, うち -53.33% の前年比減少.

次回決算発表

GH Researchの決算発表予定日は Nov 5, 2026, 寄り付き前の予定です。
アナリストの売上高予想は ... アップグレード

ニュース

4週間前 · Simply Wall St.

Is GH Research (GHRS) Trading At A Premium To Fair Value?

GH Research stock has delivered strong gains over the past few years, yet its latest valuation checks suggest the shares may now be priced on the expensive side rather than offering clear value. Over ...

1か月前 · Stocktwits

CMPS, MDGL, DFTX, GHRS, HELP Stocks In Spotlight Today – Why Wells Fargo Thinks Next Wave Of Depression Drugs Could Create New Winners

Wells Fargo began coverage on five biotech stocks on Monday, with only Compass Pathways receiving an ‘Equal-Weight’ rating while the rest received ‘Overweight’ ratings.

1か月前 · 24/7 Wall St.

Eli Lilly Buys Psychedelics Maker Atai Beckley for $2.8 Billion to Develop DMT-Like Depression Drug

Eli Lilly just wrote a $2.8 billion check on a psychedelic nasal spray that won't have pivotal trial data until 2029, and the reasoning behind that bet reveals where Big Pharma thinks depression treat...

1か月前 · Investing.com

Why Psychedelic stocks are surging today

Investing.com -- Shares of psychedelic drug developers are surging premarket on Thursday after Eli Lilly announced a definitive agreement to acquire AtaiBeckley Inc., validating the sector and lifting...

1か月前 · InvestorsHub

GH Research gains on optimism surrounding potential Eli Lilly-Atai deal (GHRS)

GH Research (NASDAQ:GHRS) shares climbed around 12% in premarket trading on Thursday after reports that Eli Lilly (NYSE:LLY) is in discussions to acquire psychedelic drug developer Atai Life Sciences ...

2ページ中1ページ